pharmaphorum

FEBRUARY 18, 2022

The pandemic-induced transition to digital health is, according to the Nuffield Trust, contributing to an “inverse care law” that’s compounding existing health inequalities. But, as demonstrated by initiatives like the Telehealth Equity Coalition (TEC), the sector is taking a united stand against inequitable access. Technological solutions, from online clinics to app-based long-term condition management, have long been hailed as a solution to problems such as limited capacity and low patient aut

Compounding 109

Compounding 109

Fossil Remedies

FEBRUARY 18, 2022

PCD Pharma Franchise Business. Why are more aspirants willing to make a career in the field of pharmaceuticals? It is because the business is not only promising, but it is going to remain profitable for many years. People have become health conscious and they want to maintain fitness. Also, the recent Covid-19 outbreak has also changed the scenario.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

FEBRUARY 18, 2022

Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don’t respond to the only approved biologic treatment, Novartis/Roche’s Xolair. . CSU is a severe form of hives that affects around 1% of the global population, causing severe itching and swelling that can last for weeks at a time and resist even very high doses of antihistamines, the standard, first-line therapy for the condition.

99

99

Pharma Mirror

FEBRUARY 18, 2022

Dean Kavanagh, Managing Director of QED Environmental Systems Ltd in the UK, has been appointed Co-Chair of the Council of Gas Detection and Environmental Monitoring (CoGDEM) Industry Subgroup. Dean will chair the Sub-group with Rob White, Sales Director of DD Scientific, with both chairs taking up their appointments early in 2022. The CoGDEM Industry Subgroup is one of the most influential steering groups, with meetings scheduled three times a year.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

FEBRUARY 18, 2022

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours. The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide) follows the publication of the results of the phase 3 ARASENS trial in the New England Journal of Medicine.

Chemotherapy 98

Chemotherapy Labelling 98

Pharma Mirror

FEBRUARY 18, 2022

By Christopher Weikart, Chief Scientist, SiO2 Materials Science Even though drugs are meant to save lives, the primary packaging used for delivering drug therapies and vaccines may actually be putting us in danger. The pharmaceutical industry works hard to create cutting-edge drugs to save lives and keep people healthy. From research to clinical trials, to go-to-market, drug makers are constantly seeking out new drug technologies and approaches to treat everyday illnesses and to end global pande

Packaging 52

Packaging Vaccines 52

Pharma Marketing Network

FEBRUARY 18, 2022

Join PMN and industry experts from Novo Nordisk, Esai, GSK, Otsuka and more for part 1 of a 2 part series on engagement. The PMN HCP Engagement Summit , 03/02/2022 @ 12PM EST, will focus on HCP Engagement on the following panel topics: Modular Content: Making It Work. Get insights for pharma marketing insiders on restructuring you content strategy allowing more flexibility and agility to deliver more relative content to your customers.

52

52

pharmaphorum

FEBRUARY 18, 2022

Welcome to the 3 rd Annual RNAi – Based Therapeutics Summit : Overcoming Barriers for Targeted siRNA Therapeutics. Built with biopharmaceutical industry insights, this in person conference will bring together key opinion leaders to delve deep into the key remaining challenges associated with targeted delivery, translation, CMC and clinical development of targeted siRNA therapeutics for modular, reproducible and effective gene silencing therapies against oncology, CNS, rare diseases and beyon

52

52

Roots Analysis

FEBRUARY 18, 2022

Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. These cells are found in abundance in the tumor microenvironment and inflamed areas. The tumor recruits and modulates endogenous myeloid cells to tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells and neutrophils, to sustain an immunosuppressive environment.

Immunization 52

Immunization Vaccines 52

Pharma Times

FEBRUARY 18, 2022

New combination treatment can significantly reduce the risk of death among prostate cancer patients

54

54

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Roots Analysis

FEBRUARY 18, 2022

In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. These short, single-stranded DNA or RNA molecules have various applications in biopharmaceutical and biotechnology industries including, genetic testing, basic research, forensic analysis and other analytical procedures.

52

52

Pharma Times

FEBRUARY 18, 2022

Company focused on founding and building global leaders in life science sold to Novartis

43

43